Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNK | O75909 | 5/20 | 0.42 |
| ▸ | CDK12 | Q9NYV4 | 5/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SPR | P35270 | 1/20 | 0.40 |
| ▸ | GLS | O94925 | 1/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 3/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 2/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | IL1B | P01584 | 1/20 | 0.38 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22655181 | 0.92 | IL1B (0.43) | CCNKCDK12LMNAHTTFAAH | |
| SCHEMBL22655179 | 0.92 | IL1B (0.43) | CCNKCDK12LMNAHTTFAAH | |
| SCHEMBL29017114 | 0.84 | BTK (0.40) | CCNKCDK12GLSENPP2JAK3 | |
| SCHEMBL29017118 | 0.84 | BTK (0.40) | CCNKCDK12GLSENPP2JAK3 | |
| SCHEMBL18890332 | 0.82 | USP30 (0.50) | HTTBTK | |
| SCHEMBL22654897 | 0.82 | JAK3 (0.38) | CCNKCDK12LMNAHTTFAAH | |
| SCHEMBL23523150 | 0.81 | CHRM4 (0.38) | LMNAHTTFAAHACHEMEN1 | |
| SCHEMBL23523148 | 0.81 | CHRM4 (0.38) | LMNAHTTFAAHACHEMEN1 | |
| SCHEMBL23523152 | 0.81 | CHRM4 (0.38) | LMNAHTTFAAHACHEMEN1 | |
| SCHEMBL29919576 | 0.81 | CHRM4 (0.38) | LMNAHTTFAAHACHEMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108349967-B | 1,3, 4-thiadiazole compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2022-02-15 | — | — | CN | disclosed |
| CN-108349951-B | Bispyridazine compound | 阿斯利康(瑞典)有限公司 | 2020-11-13 | — | — | CN | disclosed |
| EP-3380468-B1 | BIS-PYRIDAZINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2020-05-20 | — | — | EP | disclosed |
| US-10577354-B2 | Bis-pyridazine compounds and their use in treating cancer | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2020-03-03 | — | — | US | disclosed |
| EP-3383871-B1 | 1,3,4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2019-09-11 | — | — | EP | disclosed |
| US-20190169172-A1 | bis-Pyridazine Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2019-06-06 | — | — | US | disclosed |
| US-10196382-B2 | bis-Pyridazine compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2019-02-05 | — | — | US | disclosed |
| EP-3380468-A1 | BIS-PYRIDAZINE COMPOUNDS AND THEIR USE IN TREATING CANCER | Astrazeneca AB (SE) | 2018-10-03 | — | — | EP | disclosed |
| WO-2017089587-A1 | BIS-PYRIDAZINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2017-06-01 | — | — | WO | disclosed |
| US-20170152244-A1 | bis-Pyridazine Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2017-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10196382-B2 | bis-Pyridazine compounds and their use in treating cancer | GLS2, GLS, GLUL | CCNK 1439/4885CDK12 914/4885LMNA 4250/4885 |
| US-10577354-B2 | Bis-pyridazine compounds and their use in treating cancer | GLS2, GLS, GLUL | CCNK 1439/4885CDK12 914/4885LMNA 4250/4885 |
| US-20190169172-A1 | bis-Pyridazine Compounds and Their Use in Treating Cancer | GLS2, GLS, GLUL | CCNK 863/4885CDK12 571/4885LMNA 4046/4885 |
| US-20170152244-A1 | bis-Pyridazine Compounds and Their Use in Treating Cancer | GLS2, GLS, GLUL | CCNK 1439/4885CDK12 914/4885LMNA 4250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.